Author/Authors :
Glatter، نويسنده , , Kathryn A and Wang، نويسنده , , Qing and Keating، نويسنده , , Mark and Chen، نويسنده , , Shenghan and Chiamvimonvat، نويسنده , , Nipavan and Scheinman، نويسنده , , Melvin M، نويسنده ,
Abstract :
We describe a 53-year-old man with recurrent syncopal events and a malignant family history who was treated for 13 years with sotalol drug therapy with no further occurrence of Brugada syndrome symptoms. Genetic testing revealed that he carried a Brugada syndrome sodium channel SCN5A mutation (4189delT). This finding suggests that sotalol may be of therapeutic benefit in such patients.
